To examine if HLA‐A*02:01 and HLA‐A*24:02 are associated with prostate cancer progression after radical prostatectomy, we analyzed two prospective North American cohorts: one with mainly early‐stage (AJCC 8th edition clinical stage I–II; 97%; CPC‐GENE, n = 229) and one with mainly later‐stage prostate cancer (AJCC 8th edition clinical stage III–IV; 68%, TCGA‐PRAD, n = 441; n = 345 with data that allowed clinical staging; Fig. 1A, Table S1). The gene discussed is HLA-A; the disease is prostate carcinoma.